Overview

We were formed in 2014 by neuroscience researchers at the Swiss Federal Institute of Technology (EPFL). We are now headquartered at the High Tech Campus in Eindhoven, the Netherlands, with an office in Lausanne, Switzerland and a growing US team based in Boston, Massachusetts.

Meet the team

  • Dave Marver, CEO

    Dave Marver

    Chief Executive Officer

    Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles.
  • John Murphy, PhD, CTO

    John Murphy, PhD

    Chief Technology Officer

    John Murphy has over 25 years of experience driving the development of medical implants and neurostimulation devices at LivaNova, Abbott, and Medtronic. His leadership expertise spans the continuum of R&D, with a focus on consumer-centric design, IP generation, and agile processes. Prior to joining ONWARD in 2020, John was the Chief Technology Officer of LivaNova Neuromodulation. He holds a BS in Electrical Engineering from the University of North Carolina at Charlotte and a PhD in Production Systems and Robotics from the Swiss Federal Institute of Technology (EPFL).
  • Khaled Bahi

    Khaled Bahi

    Interim Chief Financial Officer

    Khaled Bahi is the former CFO of Symetis, which was acquired by Boston Scientific in 2017 for $435M. He has over 20 years of medtech experience in a variety of finance leadership positions, including as the former CFO of Stilla Technologies in France and as a former finance leader for Fresenius Medical Care in France, Europe, Middle East, and Africa. Khaled earned an MSc from ETH Zürich.

  • Erika

    Erika Ross, PhD

    Vice President, Global Clinical & Regulatory

    Erika Ross brings extensive expertise in neuromodulation, with experience in clinical trial design and execution for class II and III neurostimulation technologies.  She joins ONWARD from Abbott Neuromodulation, where she was Director, Global Clinical & Applied Research. Previously, as Neuroscience Director at Cala Health, she managed the scientific research program that led to de novo clearance and launch of the company’s neurostimulation technology. She also brings outstanding relationships with researchers and clinicians, forged during her years as Deputy Director, Medical Device Innovation Accelerator, Department of Surgery, and Assistant Professor, Department of Neurologic Surgery at Mayo Clinic. Erika holds a BSc in Biology and Business and an MSc in Molecular Biology from the University of Denver and a PhD in Neuroscience from Mayo Clinic.
  • Sarah

    Sarah Moore

    Vice President, Global Marketing

    Sarah Moore has over 20 years of healthcare marketing, sales, and business development experience, including strategy, product planning, and M&A. Before joining ONWARD, Sarah was Head of Commercial Marketing at Nevro, an implantable neuromodulation company. Prior to that, she held various leadership roles in global marketing across multiple Johnson & Johnson medical device franchises, most recently as the business unit leader for J&J’s Advanced Imaging business. Sarah earned an MBA from Duke University and a BA in German from Washington and Lee University.

Recent News

02 May 24
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions
EINDHOVEN, the Netherlands — May 2, 2024 —ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024.
25 Apr 24
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
EINDHOVEN, the Netherlands — April 25, 2024 — ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its Full Year 2023 Financial and Operating Results.
11 Apr 24
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
EINDHOVEN, the Netherlands — April 11, 2024 — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will publish Full Year 2023 Financial Results and host a webcast to discuss business highlights.
09 Apr 24
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price of EUR 5.00 on April 8, 2024.

Financial Calendar

Recent Filings

ESG Information